MedicaidPrior AuthMedium impact
Niktimvo™ (axatilimab-csfr) (New)
Humana·IN · Oncology, Hematology, Internal Medicine·Medicaid
Effective date
Jul 1, 2026
We identified it
Jul 2, 2026
Summary
Humana Indiana Medicaid has established a new prior authorization policy for Niktimvo™ (axatilimab-csfr), a specialized IV infusion therapy for chronic Graft vs Host Disease (cGVHD). Billing teams must now obtain prior authorization before dispensing this drug, requiring verification that patients meet three specific clinical criteria: confirmed cGVHD diagnosis, failure of at least two prior systemic therapies, and minimum weight of 40 kg. This policy is effective immediately and applies to all Niktimvo intravenous solution administration under Indiana Medicaid.
Action Required
By July 1, 2026: Billing and clinical teams must implement prior authorization requirements for all Niktimvo (axatilimab-csfr) intravenous infusions for Indiana Medicaid members. Specifically: (1) Update billing system to flag all Niktimvo claims as requiring prior auth; (2) Create pre-authorization checklist requiring verification of: patient diagnosis of cGVHD, documentation of failure with at least 2 prior systemic therapy lines, and patient weight ≥40 kg; (3) Train pharmacy and billing staff to submit PA requests to Humana before dispensing; (4) Update provider encounter forms and clinical documentation templates to capture required criteria; (5) Establish workflow to route Niktimvo requests through PA approval process before claim submission. Consequence: Claims submitted without prior authorization will be denied. Reference Humana PAL website (www.humana.com/PAL) for applicable medical and procedural coding information.